Status | Study |
RECRUITING |
Study Name: FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role Condition: Marginal Zone Lymphoma Date: 2020-03-31 |
Not yet recruiting |
Study Name: A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) Condition: Relapsed Marginal Zone Lymphoma Refractory Date: 2017-05-05 Interventions: Drug: INCB050465 INCB050465 at the protocol-defined dose. |
Recruiting |
Study Name: Prospective Study of Frontline H Pylori Eradication in the Treatment of Early-stage Extragastric MALT Lymphoma Condition: Mucosa-Associated Lymphoid Tissue Lymphoma Date: 2016-12-01 |
Not yet recruiting |
Study Name: Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma Condition: Splenic Marginal Zone Lymphoma Date: 2016-10-23 |
Active, not recruiting |
Study Name: Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma Condition: Marginal Zone B-cell Lymphoma Date: 2016-07-26 Interventions: Drug: Bendamustine and Rituximab |
Recruiting |
Study Name: Marginal Zone Lymphoma Cohort in Korea Condition: Lymphoma, B-Cell, Marginal Zone Date: 2016-04-04 Interventions: Other: Rituximab Cohort observation study |
Recruiting |
Study Name: Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) Condition: Marginal Zone B-cell Lymphoma Date: 2015-04-05 Interventions: Drug: bendamustine plus rituximab Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 |
Terminated |
Study Name: Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Condition: Follicular Lymphoma Chronic Lymphocytic Leukemia Small Lym Date: 2014-10-03 Interventions: Drug: GS-9901 GS-9901 tablets administered orally |
Active, not recruiting |
Study Name: Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma Condition: Marginal Zone Lymphoma B-cell Lymphoma Date: 2013-10-29 Interventions: Drug: ibrutinib |
Active, not recruiting |
Study Name: Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment Condition: Marginal Zone Lymphoma of Ocular Adnexal Date: 2013-03-26 Interventions: Drug: Doxycycline All enrolled patients will be treated with doxycycline 100 mg bid daily, orally, for f |